“AI Regulations: Are Global Life Science Collaborations at Risk? 85% of Professionals Sound the Alarm!”
In an era where artificial intelligence is no longer just a technological marvel but an integral part of research and development, the intersection of AI and copyright concerns looms large in the life sciences. Have you ever wondered how an innovative tool like generative AI can thrive while treading the murky waters of copyright compliance? Well, the recent findings from the Pistoia Alliance’s latest survey might just hold the key. Gathering over 200 experts—from the Chan Zuckerberg Initiative and FDA to AbbVie and Takeda—the annual conference in Philadelphia unveiled some startling statistics: a staggering 83% of life science professionals are now diving into generative AI for their research, yet a chilling 85% are anxious about the impact of inconsistent AI regulations across borders. What gives? A considerable 42% admit they don’t even think about copyright before utilizing third-party information with these AI tools! As we explore these insights and the pivotal discussions around patient-centricity and data standards, one thing is clear: collaboration and awareness are essential in navigating this complex landscape. Curious about how these findings could shape the future of life sciences and R&D? You’re not alone—let’s dive deeper into this pressing issue! LEARN MORE
Experts From Chan Zuckerberg Initiative, FDA, AbbVie, Elsevier, Penn Medicine, Takeda and Others Discuss Patient-Centricity, Data Standards, and Copyright
London, 10 December 2024: The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has announced the results of a global survey in conjunction with CCC (Copyright Clearance Center), a leader in advancing copyright, accelerating knowledge, and powering innovation, on the impact of AI and copyright legislation on pharma R&D. While 83% of life science professionals are now using generative AI in their research, there is still widespread concern about the impact of differing AI regulations on cross-border research collaboration (85%). Additionally, 42% of respondents said they don’t think about copyright before sharing or using third-party information with AI tools. The survey was conducted at the Alliance’s annual US conference held this year in Philadelphia, which gathered more than 200 industry experts to collaborate on topics such as AI regulation, harmonization of data standards, and patient-centricity.
Post Comment